65 related articles for article (PubMed ID: 23094178)
1. A Comparative Study of Efficacy and Safety of Agomelatine and Escitalopram in Major Depressive Disorder.
Komaram RB; Nukala S; Palla J; Nambaru LR; Kasturi SM
J Clin Diagn Res; 2015 Jun; 9(6):VC05-VC08. PubMed ID: 26266196
[TBL] [Abstract][Full Text] [Related]
2. Agomelatine versus other antidepressive agents for major depression.
Guaiana G; Gupta S; Chiodo D; Davies SJ; Haederle K; Koesters M
Cochrane Database Syst Rev; 2013 Dec; (12):CD008851. PubMed ID: 24343836
[TBL] [Abstract][Full Text] [Related]
3. Agomelatine augmentation in obsessive compulsive disorder: a preliminary report.
Tzavellas E; Karaiskos D; Ilias I; Liappas I; Paparrigopoulos T
Psychiatriki; 2014; 25(3):179-84. PubMed ID: 25367661
[TBL] [Abstract][Full Text] [Related]
4. Agomelatine augmentation of sertraline in the treatment of moderate to severe obsessive-compulsive disorder: a randomized double-blinded placebo-controlled clinical trial.
Shokrani M; Askari S; Eissazade N; Shariat SV; Shariati B; Yarahmadi M; Shalbafan M
BMC Psychiatry; 2023 Sep; 23(1):686. PubMed ID: 37735631
[TBL] [Abstract][Full Text] [Related]
5. What combinations of agomelatine with other antidepressants could be successful during the treatment of major depressive disorder or anxiety disorders in clinical practice?
Potměšil P
Ther Adv Psychopharmacol; 2019; 9():2045125319855206. PubMed ID: 31312426
[TBL] [Abstract][Full Text] [Related]
6. Venlafaxine augmentation with agomelatine in a patient with obsessive-compulsive disorder and suicidal behaviors.
Signorelli MS; Concerto C; Battaglia E; Costanzo MC; Battaglia F; Aguglia E
SAGE Open Med Case Rep; 2014; 2():2050313X14561778. PubMed ID: 27489668
[TBL] [Abstract][Full Text] [Related]
7. OCDB: a database collecting genes, miRNAs and drugs for obsessive-compulsive disorder.
Privitera AP; Distefano R; Wefer HA; Ferro A; Pulvirenti A; Giugno R
Database (Oxford); 2015; 2015():bav069. PubMed ID: 26228432
[TBL] [Abstract][Full Text] [Related]
8. Microstructural abnormality in left nucleus accumbens predicts dysfunctional beliefs in treatment-resistant obsessive-compulsive disorder.
Li Z; Ji W; Li D; Li X; Feng W
Med Sci Monit; 2014 Nov; 20():2275-82. PubMed ID: 25393961
[TBL] [Abstract][Full Text] [Related]
9. Agomelatine-induced hepatotoxicity.
Štuhec M
Wien Klin Wochenschr; 2013 Apr; 125(7-8):225-6. PubMed ID: 23519541
[No Abstract] [Full Text] [Related]
10. Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study.
Fornaro M; McCarthy MJ; De Berardis D; De Pasquale C; Tabaton M; Martino M; Colicchio S; Cattaneo CI; D'Angelo E; Fornaro P
Neuropsychiatr Dis Treat; 2013; 9():243-51. PubMed ID: 23430979
[TBL] [Abstract][Full Text] [Related]
11. A benzisothiazole derivative and antipsychotic agent, perospirone, for augmentation of selective serotonin reuptake inhibitors (SSRIs) in refractory obsessive-compulsive disorder (OCD): two patient case series.
Matsunaga H; Matsui T; Ohya K; Okino K; Hayashida K; Maebayashi K; Kiriike N; Stein DJ
Int J Psychiatry Clin Pract; 2006; 10(2):142-5. PubMed ID: 24940965
[TBL] [Abstract][Full Text] [Related]
12. Antipsychotic treatment in obsessive-compulsive disorder: a literature review.
Keuneman RJ; Pokos V; Weerasundera R; Castle DJ
Aust N Z J Psychiatry; 2005 May; 39(5):336-43. PubMed ID: 15860020
[TBL] [Abstract][Full Text] [Related]
13. Management of obsessive-compulsive disorder.
Seibell PJ; Hollander E
F1000Prime Rep; 2014; 6():68. PubMed ID: 25165567
[TBL] [Abstract][Full Text] [Related]
14. Agomelatine augmentation of escitalopram therapy in treatment-resistant obsessive-compulsive disorder: a case report.
De Berardis D; Serroni N; Marini S; Martinotti G; Ferri F; Callista G; La Rovere R; Moschetta FS; Di Giannantonio M
Case Rep Psychiatry; 2012; 2012():642752. PubMed ID: 23094178
[TBL] [Abstract][Full Text] [Related]
15. Ziprasidone Augmentation in an Adolescent with Obsessive Compulsive Disorder: A Case Report.
Demirkaya SK; Alyanak B
Psychopharmacol Bull; 2016 Mar; 46(1):73-76. PubMed ID: 27738375
[TBL] [Abstract][Full Text] [Related]
16. Moving beyond first-line treatment options for OCD.
Paxos C
Ment Health Clin; 2022 Oct; 12(5):300-308. PubMed ID: 36405507
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
